Haloperidol concentrations in patients with Alzheimer's dementia

M. W. Dysken, S. B. Johnson, L. Holden, G. Vatassery, J. Nygren, M. Jelinski, M. Kuskowski, L. Schut, J. R. McCarten, David S Knopman, G. J. Maletta, S. Skare

Research output: Contribution to journalArticle

13 Scopus citations


To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE- AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalAmerican Journal of Geriatric Psychiatry
Issue number2
StatePublished - 1994
Externally publishedYes


ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Dysken, M. W., Johnson, S. B., Holden, L., Vatassery, G., Nygren, J., Jelinski, M., Kuskowski, M., Schut, L., McCarten, J. R., Knopman, D. S., Maletta, G. J., & Skare, S. (1994). Haloperidol concentrations in patients with Alzheimer's dementia. American Journal of Geriatric Psychiatry, 2(2), 124-133. https://doi.org/10.1097/00019442-199405000-00006